Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Reclassified as terminated (was completed) Sponsor's reason: Sponsor stopped enrollment at 50 of 70 planned patients because an activity signal had been observed in lymphoma and further enrollment would not add significantly to interpretation of efficacy or safety.
    • Primary and study completion dates: Apr 2012 to Jun 30, 2009
    • Start date: Dec 2006 to Dec 29, 2006
    v9
  3. Re-verified, no change to tracked fieldsv8
  4. Primary and study completion dates changed from estimate of Jun 2009 to Apr 2012
    • Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 70 to confirmed 50
    v7
  5. Re-verified, no change to tracked fieldsv6
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites revised (6)
    v5
  2. Study sites revised (6)v4
  3. Enrollment target: 40 to 70
    • Primary and study completion dates: Aug 2008 to Jun 2009
    • Study sites: 11 to 6
    • Eligibility criteria shortened, about 7 words
    v3
  4. Study sites: 4 to 11v2 Show 5 more changesShow less
    • Primary and study completion dates: Aug 2008
    • Start date: Dec 2006
    • Interventions: ZIO-101 (Drug) to Darinaparsin (Drug)
    • Eligibility criteria expanded, about 211 words
    • Study arms: 0 to 1
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
Trial Details
NCT Number NCT00421213
Lead Sponsor Alaunos Therapeutics
Conditions
(from sponsor)		 Hematologic Neoplasms, Bone Marrow Neoplasms, Non-Hodgkin's Lymphoma
Related terms Bone Marrow Neoplasms, Hematologic Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov